Incyte’s bet on Escient hits a snag as safety issues hamper Phase 2 chronic hives trial
Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was flagged with safety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
